Alzheimer’s blood test could boost research after successive trial failuresA blood test could be used to diagnose Alzheimer’s before symptoms arise, providing an alternative to expensive brain Share XAlzheimer’s blood test could boost research after successive trial failureshttps://pharmaphorum.com/news/alzheimers-blood-test-could-boost-research-after-successive-trial-failures/
FDA fast-tracks NeuroVive’s traumatic brain injury drugThe FDA has fast-tracked a drug to treat severe traumatic brain injury from Swedish pharma NeuroVive, hastening its Share XFDA fast-tracks NeuroVive’s traumatic brain injury drughttps://pharmaphorum.com/news/fda-fast-tracks-neurovives-traumatic-brain-injury-drug/
Neurametrix aims to expand Alzheimer’s typing test in Pacific regionUS medical device firm Neurametrix has struck an agreement with N-Strategy Consulting Services (NSCS) to invest in a Share XNeurametrix aims to expand Alzheimer’s typing test in Pacific regionhttps://pharmaphorum.com/news/neurametrix-aims-to-expand-alzheimers-typing-test-in-pacific-region/
Intec Pharma shares dive after Parkinson’s trial failureIntec Pharma’s Parkinson’s gradual release disease drug trial has missed its primary endpoint, causing the biotech’s share price Share XIntec Pharma shares dive after Parkinson’s trial failurehttps://pharmaphorum.com/news/intec-pharma-shares-dive-after-parkinsons-trial-failure/
Musk’s Neuralink close to clinical trials of “brain interface” deviceA new brain implant technology from Elon Musk’s tech startup Neuralink could be used as a treatment for Share XMusk’s Neuralink close to clinical trials of “brain interface” devicehttps://pharmaphorum.com/news/musks-neuralink-close-to-clinical-trials-of-brain-interface-device/
FDA fast tracks Prevail’s Parkinson’s gene therapyThe FDA has fast tracked a gene therapy for a certain form of Parkinson’s Disease from US biotech Share XFDA fast tracks Prevail’s Parkinson’s gene therapyhttps://pharmaphorum.com/news/fda-fast-tracks-prevails-parkinsons-gene-therapy/
Under threat from Novartis, Biogen hails new data from SMA drug SpinrazaUnder threat from a gene therapy from Novartis, Biogen is making the case for its drug Spinraza for Share XUnder threat from Novartis, Biogen hails new data from SMA drug Spinrazahttps://pharmaphorum.com/news/under-threat-from-novartis-biogen-hails-new-data-from-sma-drug-spinraza/
Sanofi hands back neurology gene therapy rights to VoyagerSanofi’s Genzyme unit has handed back rights to two neurology gene therapies to US biotech Voyager Therapeutics, as Share XSanofi hands back neurology gene therapy rights to Voyagerhttps://pharmaphorum.com/news/sanofi-hands-back-neurology-gene-therapy-rights-to-voyager/
Bayer’s regorafenib kicks off brain cancer platform trialBayer has become the first pharma company to take part in a new platform trial designed to find Share XBayer’s regorafenib kicks off brain cancer platform trialhttps://pharmaphorum.com/news/bayers-regorafenib-kicks-off-brain-cancer-platform-trial/
